ATE365042T1 - Verwendung von morpholinol zur behandlung von sexuellen funktionsstörungen - Google Patents

Verwendung von morpholinol zur behandlung von sexuellen funktionsstörungen

Info

Publication number: ATE365042T1
Authority: AT; Austria
Prior art keywords: morpholinol; sexual disorders; treat sexual; treat; disorders
Prior art date: 1998-01-21

Application number

AT99903200T

Other languages

English (en)

Inventor

Phillip Morgan

David Musso

John Partridge

Original Assignee

Glaxo Group Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-01-21

Filing date

1999-01-20

Publication date

2007-07-15

1998-01-21 Priority claimed from GBGB9801230.5A external-priority patent/GB9801230D0/en

1999-01-20 Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd

2007-07-15 Application granted granted Critical

2007-07-15 Publication of ATE365042T1 publication Critical patent/ATE365042T1/de

Links

OURXRFYZEOUCRM-UHFFFAOYSA-N 4-hydroxymorpholine Chemical compound ON1CCOCC1 OURXRFYZEOUCRM-UHFFFAOYSA-N 0.000 title 1
230000001568 sexual effect Effects 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Organic Chemistry (AREA)
Psychiatry (AREA)
Addiction (AREA)
Pain & Pain Management (AREA)
Epidemiology (AREA)
Psychology (AREA)
Child & Adolescent Psychology (AREA)
Diabetes (AREA)
Hematology (AREA)
Obesity (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Hospice & Palliative Care (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

AT99903200T 1998-01-21 1999-01-20 Verwendung von morpholinol zur behandlung von sexuellen funktionsstörungen ATE365042T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB9801230.5A GB9801230D0 (en)	1998-01-21	1998-01-21	Pharmaceutically active morpholinol
US7218098P	1998-01-22	1998-01-22

Publications (1)

Publication Number	Publication Date
ATE365042T1 true ATE365042T1 (de)	2007-07-15

Family

ID=26312986

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT99903200T ATE365042T1 (de)	1998-01-21	1999-01-20	Verwendung von morpholinol zur behandlung von sexuellen funktionsstörungen

Country Status (30)

Country	Link
US (2)	US6274579B1 (de)
EP (2)	EP1047428B1 (de)
JP (1)	JP2002501025A (de)
KR (1)	KR100568063B1 (de)
CN (2)	CN1203858C (de)
AP (1)	AP1229A (de)
AT (1)	ATE365042T1 (de)
AU (1)	AU755536B2 (de)
BR (1)	BR9907203A (de)
CA (1)	CA2318268A1 (de)
CY (1)	CY1106828T1 (de)
DE (1)	DE69936335T2 (de)
DK (1)	DK1047428T3 (de)
EA (1)	EA002410B1 (de)
EE (1)	EE04452B1 (de)
ES (1)	ES2288012T3 (de)
HR (2)	HRP20000494B1 (de)
HU (1)	HUP0100900A3 (de)
ID (1)	ID26334A (de)
IL (2)	IL161942A0 (de)
IS (1)	IS2494B (de)
NO (2)	NO326878B1 (de)
NZ (3)	NZ505809A (de)
PL (1)	PL193622B1 (de)
PT (1)	PT1047428E (de)
SG (1)	SG115489A1 (de)
SK (1)	SK10912000A3 (de)
TR (1)	TR200002126T2 (de)
WO (1)	WO1999037305A1 (de)
YU (1)	YU67102A (de)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7098206B2 (en) *	1998-01-21	2006-08-29	Smithkline Beecham Corporation	Pharmaceutically active morpholinol
US6998400B2 (en) *	1998-01-22	2006-02-14	Smithkline Beecham Corporation	Pharmaceutically active morpholinol
WO1999038504A1 (en)	1998-01-29	1999-08-05	Sepracor Inc.	Pharmaceutical uses of optically pure (-)-bupropion
AU2349999A (en)	1998-01-29	1999-08-16	Sepracor, Inc.	Pharmacological uses of pure (+) -bupropion
US6855820B2 (en)	1999-01-20	2005-02-15	Smithkline Beecham Corporation	Pharmaceutically active morpholinol
US6734213B2 (en)	1999-01-20	2004-05-11	Smithkline Beecham Corporation	Pharmaceutically active morpholinol
US6342496B1 (en)	1999-03-01	2002-01-29	Sepracor Inc.	Bupropion metabolites and methods of use
US6337328B1 (en) *	1999-03-01	2002-01-08	Sepracor, Inc.	Bupropion metabolites and methods of use
AU7750100A (en) *	1999-10-13	2001-04-23	Glaxo Group Limited	Method for the treatment of obesity
GB0003232D0 (en) *	2000-02-11	2000-04-05	Smithkline Beecham Plc	Novel composition
CA2365428C (en) *	2000-12-21	2008-10-21	Brasscorp Limited	Method of producing an ultra-violet or near ultra-violet light source for non-destructive inspection or testing
US6979104B2 (en)	2001-12-31	2005-12-27	R.J. Doran & Co. LTD	LED inspection lamp
MXPA04011203A (es) *	2002-05-17	2005-07-14	Univ Duke	Metodo para tratar la obesidad.
US20050215552A1 (en) *	2002-05-17	2005-09-29	Gadde Kishore M	Method for treating obesity
GB0219687D0 (en) *	2002-08-23	2002-10-02	Lilly Co Eli	Benzyl morpholine derivatives
DE60324685D1 (de) *	2002-08-23	2008-12-24	Lilly Co Eli	2-(phenylthiomethyl)- morpholin-derivate zur verwendung als selektive norepinephrin-wiederaufnahme-inhibitoren
WO2004096201A1 (en)	2003-04-29	2004-11-11	Orexigen Therapeutics, Inc.	Compositions for affecting weight loss
GB0325055D0 (en) *	2003-10-27	2003-12-03	Smithkline Beecham Corp	New process
WO2005044809A1 (en) *	2003-10-27	2005-05-19	Smithkline Beecham Corporation	Diastereomeric dynamic kinetic resolution process for preparing (+)-(2s, 3s)-2-(3-chlorophenyl)-3,5,5-trimethyl-2-morpholinol, salts, and solvates thereof
GB0326148D0 (en) *	2003-11-10	2003-12-17	Lilly Co Eli	Morpholine derivatives
GB0327195D0 (en) *	2003-11-21	2003-12-24	Smithkline Beecham Corp	Novel use
GB0327619D0 (en) *	2003-11-27	2003-12-31	Smithkline Beecham Corp	New use
EP1734955A2 (de)	2004-01-13	2006-12-27	Duke University	Zusammensetzungen eines antikonvulsiven mittels und eines antipsychotischen mittels zur beeinflussung des gewichtsverlustes
US7713959B2 (en) *	2004-01-13	2010-05-11	Duke University	Compositions of an anticonvulsant and mirtazapine to prevent weight gain
EP1748776A1 (de) *	2004-05-03	2007-02-07	Duke University	Zusammensetzungen zur beeinflussung des gewichtsverlusts
FI117283B (fi)	2005-02-04	2006-08-31	Kone Corp	Hissijärjestelmä
ES2761812T3 (es)	2005-11-22	2020-05-21	Nalpropion Pharmaceuticals Inc	Composición y métodos de aumento de la sensibilidad a la insulina
EP1968603A4 (de) *	2006-01-03	2013-01-16	Algebra Inc	Therapeutische aminarylsulfonamidkonjugatverbindungen
US8916195B2 (en)	2006-06-05	2014-12-23	Orexigen Therapeutics, Inc.	Sustained release formulation of naltrexone
KR20150082689A (ko)	2006-11-09	2015-07-15	오렉시젠 세러퓨틱스 인크.	단위 용량 팩키지
DK2089005T3 (da)	2006-11-09	2010-07-19	Orexigen Therapeutics Inc	Lagdelte farmaceutiske formuleringer omfattende et hurtigt opløsende mellemlag
US20090075994A1 (en) *	2007-09-14	2009-03-19	Protia, Llc	Deuterium-enriched radafaxine
WO2009158114A1 (en)	2008-05-30	2009-12-30	Orexigen Therapeutics, Inc.	Methods for treating visceral fat conditions
WO2010121022A1 (en)	2009-04-15	2010-10-21	Research Triangle Institute	Monoamine reuptake inhibitors
CN102724878A (zh)	2010-01-11	2012-10-10	奥雷西根治疗公司	在重度抑郁症患者中提供体重减轻疗法的方法
CA2800219C (en)	2010-05-21	2019-03-12	Research Triangle Institute	1 - phenylmorpholine derivatives as hydroxybupropion analogues for treating drug dependence
EP2571858B1 (de)	2010-05-21	2018-06-20	Research Triangle Institute	Phenylmorpholine und analoge davon
US9510405B2 (en)	2011-06-30	2016-11-29	Schneider Electric Industries Sas	Dual power SMPS for a modular lighting system
CN102670617B (zh) *	2012-04-13	2013-03-20	湖南大学	布洛芬2-（2-芳基吗啉-4-基）乙酯作为制备抗抑郁药物的应用
HUE072188T2 (hu)	2012-06-06	2025-10-28	Nalpropion Pharmaceuticals Llc	Készítmény magas kardiovaszkuláris kockázatú túlsúlyos és elhízott páciensek kezelésére szolgáló eljárásban történõ alkalmazásra
CN105949142B (zh) *	2016-05-21	2018-03-27	南华大学	具有抗抑郁活性的单一手性化合物及其制备方法和应用
RU2763728C1 (ru) *	2021-06-17	2021-12-30	Федеральное государственное автономное образовательное учреждение высшего образования "Пермский государственный национальный исследовательский университет" (ПГНИУ)	Применение 3-(2-(4-нитрофенил)-2-оксоэтилиден)морфолин-2-она в качестве средства, обладающего противомикробной активностью

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US170430A (en) *		1875-11-30		Improvement in furnaces for heating steel in tempering
GB8417170D0 (en) *	1984-07-05	1984-08-08	Wellcome Found	Heterocyclic pharmaceutical compounds
GB9108629D0 (en)	1991-04-23	1991-06-12	Wellcome Found	Heterocyclic pharmaceutical compounds,preparation and use
US6337328B1 (en)	1999-03-01	2002-01-08	Sepracor, Inc.	Bupropion metabolites and methods of use

1999
- 1999-01-20 PT PT99903200T patent/PT1047428E/pt unknown
- 1999-01-20 DE DE69936335T patent/DE69936335T2/de not_active Expired - Lifetime
- 1999-01-20 HR HR20000494A patent/HRP20000494B1/xx not_active IP Right Cessation
- 1999-01-20 SG SG200204411A patent/SG115489A1/en unknown
- 1999-01-20 IL IL16194299A patent/IL161942A0/xx unknown
- 1999-01-20 AU AU23280/99A patent/AU755536B2/en not_active Ceased
- 1999-01-20 CN CNB998042706A patent/CN1203858C/zh not_active Expired - Fee Related
- 1999-01-20 IL IL13734699A patent/IL137346A0/xx not_active IP Right Cessation
- 1999-01-20 HU HU0100900A patent/HUP0100900A3/hu unknown
- 1999-01-20 DK DK99903200T patent/DK1047428T3/da active
- 1999-01-20 NZ NZ505809A patent/NZ505809A/xx unknown
- 1999-01-20 EP EP99903200A patent/EP1047428B1/de not_active Expired - Lifetime
- 1999-01-20 EE EEP200000438A patent/EE04452B1/xx not_active IP Right Cessation
- 1999-01-20 ES ES99903200T patent/ES2288012T3/es not_active Expired - Lifetime
- 1999-01-20 CN CNB2004100085595A patent/CN1255389C/zh not_active Expired - Fee Related
- 1999-01-20 NZ NZ529316A patent/NZ529316A/en unknown
- 1999-01-20 KR KR1020007007996A patent/KR100568063B1/ko not_active Expired - Fee Related
- 1999-01-20 AP APAP/P/2000/001869A patent/AP1229A/en active
- 1999-01-20 AT AT99903200T patent/ATE365042T1/de active
- 1999-01-20 ID IDW20001597A patent/ID26334A/id unknown
- 1999-01-20 BR BR9907203-3A patent/BR9907203A/pt not_active Application Discontinuation
- 1999-01-20 EP EP07110283A patent/EP1829544A1/de not_active Withdrawn
- 1999-01-20 HR HR20051024A patent/HRP20051024A2/hr not_active Application Discontinuation
- 1999-01-20 SK SK1091-2000A patent/SK10912000A3/sk unknown
- 1999-01-20 EA EA200000691A patent/EA002410B1/ru not_active IP Right Cessation
- 1999-01-20 NZ NZ520349A patent/NZ520349A/en unknown
- 1999-01-20 CA CA002318268A patent/CA2318268A1/en not_active Abandoned
- 1999-01-20 JP JP2000528287A patent/JP2002501025A/ja active Pending
- 1999-01-20 US US09/233,531 patent/US6274579B1/en not_active Expired - Fee Related
- 1999-01-20 TR TR2000/02126T patent/TR200002126T2/xx unknown
- 1999-01-20 PL PL99342012A patent/PL193622B1/pl not_active IP Right Cessation
- 1999-01-20 WO PCT/US1999/001134 patent/WO1999037305A1/en not_active Ceased
2000
- 2000-07-20 NO NO20003721A patent/NO326878B1/no not_active IP Right Cessation
- 2000-07-20 IS IS5568A patent/IS2494B/is unknown
2001
- 2001-06-22 US US09/886,391 patent/US6391875B2/en not_active Expired - Fee Related
2002
- 2002-09-06 YU YU67102A patent/YU67102A/sh unknown
2007
- 2007-08-31 CY CY20071101117T patent/CY1106828T1/el unknown
2008
- 2008-08-14 NO NO20083529A patent/NO20083529L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
EP1047428A4 (de)	2001-12-19
US20020019396A1 (en)	2002-02-14
EA002410B1 (ru)	2002-04-25
NZ520349A (en)	2004-02-27
IS5568A (is)	2000-07-20
US6274579B1 (en)	2001-08-14
CN1294513A (zh)	2001-05-09
CN1255389C (zh)	2006-05-10
SK10912000A3 (sk)	2001-04-09
NO326878B1 (no)	2009-03-09
PL342012A1 (en)	2001-05-07
AU755536B2 (en)	2002-12-12
HRP20051024A2 (hr)	2006-04-30
CY1106828T1 (el)	2012-05-23
YU67102A (sh)	2004-12-31
EP1047428A1 (de)	2000-11-02
IL137346A0 (en)	2001-07-24
HRP20000494A2 (en)	2000-12-31
NZ529316A (en)	2004-05-28
ID26334A (id)	2000-12-14
SG115489A1 (en)	2005-10-28
EP1829544A1 (de)	2007-09-05
AU2328099A (en)	1999-08-09
BR9907203A (pt)	2000-10-17
CN1528753A (zh)	2004-09-15
JP2002501025A (ja)	2002-01-15
DE69936335T2 (de)	2008-02-28
EA200000691A1 (ru)	2001-04-23
NO20003721D0 (no)	2000-07-20
HUP0100900A2 (hu)	2002-05-29
ES2288012T3 (es)	2007-12-16
IS2494B (is)	2009-02-15
DK1047428T3 (da)	2007-10-08
PL193622B1 (pl)	2007-02-28
IL161942A0 (en)	2005-11-20
EE04452B1 (et)	2005-04-15
TR200002126T2 (tr)	2000-12-21
EE200000438A (et)	2001-12-17
NO20003721L (no)	2000-09-19
DE69936335D1 (de)	2007-08-02
US6391875B2 (en)	2002-05-21
PT1047428E (pt)	2007-09-07
HRP20000494B1 (en)	2009-02-28
AP1229A (en)	2003-12-04
WO1999037305A1 (en)	1999-07-29
NZ505809A (en)	2002-09-27
CN1203858C (zh)	2005-06-01
EP1047428B1 (de)	2007-06-20
KR20010034285A (ko)	2001-04-25
AP2000001869A0 (en)	2000-09-30
HUP0100900A3 (en)	2002-08-28
NO20083529L (no)	2000-09-19
CA2318268A1 (en)	1999-07-29
KR100568063B1 (ko)	2006-04-07

Legal Events

Date

Code

Title

Description

2007-10-15

UEP

Publication of translation of european patent specification

Ref document number: 1047428

Country of ref document: EP

Publication	Publication Date	Title
DE69936335D1 (de)	2007-08-02	Verwendung von morpholinol zur behandlung von sexuellen funktionsstörungen
ATE288748T1 (de)	2005-02-15	Verwendung von retigabin zur behandlung von neuropathischen schmerzen
ATE269866T1 (de)	2004-07-15	Intranasale zubereitungen zur behandlung sexueller störungen
ATE247987T1 (de)	2003-09-15	Behandlung zur beseitigung von gerüchen
DE69722681D1 (de)	2003-07-10	Verwendung von anti-mikrotubuli mitteln zur behandlung von entzündlichen darmerkrankungen
ATE247117T1 (de)	2003-08-15	Pyrazolopyrimidinone cgmp pde5 inhibitoren zur behandlung von sexualfunktionsstörungen
DE69922914D1 (de)	2005-02-03	Stimulationssystem zur Behandlung von Erkrankungen bezüglich des Magenspeiseröhrenreflux
DE69925306D1 (de)	2005-06-16	Behandlung von kohlenwasserstoffgas
ATE419856T1 (de)	2009-01-15	Verwendung von rimexolon zur behandlung von augentrockenheit
ATE456375T1 (de)	2010-02-15	Verwendung von botulinum toxin zur behandlung von neuralgischen schmerzen
ATE452642T1 (de)	2010-01-15	Verwendung von cox-2 inhibitoren zur behandlung von affectiven störungen
ATE353218T1 (de)	2007-02-15	Verwendung von epinastin zur behandlung von allergischer rhinitis/konjunktivitis
ATE281167T1 (de)	2004-11-15	Verwendung von makroliden zur behandlung von trockenen augen
ATE526982T1 (de)	2011-10-15	Verwendung von neublastin-polypeptide zur behandlung von neuropathischen schmerzen
ATE339955T1 (de)	2006-10-15	Verwendung von escitalopram zur behandlung von generalisierten angstzuständen
ATE218862T1 (de)	2002-06-15	Verwendung von 1-hydroxy-2-pyridonen zur behandlung von hautinfektionen
ATE410181T1 (de)	2008-10-15	Verwendung von intereferon gamma zur behandlung von herzhypertrophie
ATE326969T1 (de)	2006-06-15	Verwendung von apomorphin zur behandlung der vorzeitigen ejakulation
ATE270102T1 (de)	2004-07-15	Verwendung von benzopyranolen zur behandlung von neurologischen erkrankungen
DE50105735D1 (de)	2005-04-28	Chlorzoxazon zur behandlung von psoriasis
ATE209891T1 (de)	2001-12-15	Verwendung von 1-hydroxy-2-pyridonen zur behandlung der seborrhoischen dermatitis
ATE317261T1 (de)	2006-02-15	Verwendung von mirtazapin zur behandlung von schlafstörungen
ATE190486T1 (de)	2000-04-15	Verwendung von buckminsterfulleren zur behandlung neurotoxischer verletzungen
DE69518438D1 (de)	2000-09-21	Behandlung von übereregten nervenzellenfunktionen
DE60103503D1 (de)	2004-07-01	Verwendung von fsh zur behandlung von infertilität